Some bat­tle test­ed neu­ro­science vets are go­ing all out on ear­ly on­set de­men­tia — with a $44M launch round to build the team

Ger­hard Koenig

Any­one who spe­cial­izes in neu­ro­sciences R&D has to pre­pare them­selves for some frus­tra­tion along the way. And the team at Arku­da Ther­a­peu­tics can tell you all about it.

The CEO and co-founder is Ger­hard Koenig, who you may re­call head­ed up the team at Quar­tet Med­i­cines, which worked on neu­ronal and in­flam­ma­to­ry cells, un­til they fold­ed the shop af­ter run­ning in­to a blind al­ley. Be­fore that, he was CSO at Fo­rum, which Deb­o­rah Dun­sire — now CEO at Lund­beck — had helmed as it tried to break new ground in Alzheimer’s and schiz­o­phre­nia.

It didn’t work out ei­ther.

But even though At­las closed the check­book on Quar­tet, Bruce Booth nev­er blamed the crew. You want to try some­thing cut­ting edge here, you pay your mon­ey and you take your chances. And some­times you write off your loss­es.

That’s biotech.

So now Koenig and some of the ex­ecs he’s known along the way are back, knock­ing the door on a new ap­proach to neu­rode­gen­er­a­tion, an­oth­er high-risk, high-re­ward play where they are look­ing to break new ground. And Booth has been bankrolling the in­cu­ba­tor work in hopes of see­ing a new ven­ture fly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER